The cuproptosis-related signature predicts the prognosis and immune microenvironments of primary diffuse gliomas: a comprehensive analysis.

IF 3.8 3区医学 Q2 GENETICS & HEREDITY

Human Genomics Pub Date : 2024-07-02 DOI:10.1186/s40246-024-00636-2

Tao Chang, Yihan Wu, Xiaodong Niu, Zhiwei Guo, Jiahao Gan, Xiang Wang, Yanhui Liu, Qi Pan, Qing Mao, Yuan Yang

{"title":"The cuproptosis-related signature predicts the prognosis and immune microenvironments of primary diffuse gliomas: a comprehensive analysis.","authors":"Tao Chang, Yihan Wu, Xiaodong Niu, Zhiwei Guo, Jiahao Gan, Xiang Wang, Yanhui Liu, Qi Pan, Qing Mao, Yuan Yang","doi":"10.1186/s40246-024-00636-2","DOIUrl":null,"url":null,"abstract":"Background: Evidence has revealed a connection between cuproptosis and the inhibition of tumor angiogenesis. While the efficacy of a model based on cuproptosis-related genes (CRGs) in predicting the prognosis of peripheral organ tumors has been demonstrated, the impact of CRGs on the prognosis and the immunological landscape of gliomas remains unexplored.Methods: We screened CRGs to construct a novel scoring tool and developed a prognostic model for gliomas within the various cohorts. Afterward, a comprehensive exploration of the relationship between the CRG risk signature and the immunological landscape of gliomas was undertaken from multiple perspectives.Results: Five genes (NLRP3, ATP7B, SLC31A1, FDX1, and GCSH) were identified to build a CRG scoring system. The nomogram, based on CRG risk and other signatures, demonstrated a superior predictive performance (AUC of 0.89, 0.92, and 0.93 at 1, 2, and 3 years, respectively) in the training cohort. Furthermore, the CRG score was closely associated with various aspects of the immune landscape in gliomas, including immune cell infiltration, tumor mutations, tumor immune dysfunction and exclusion, immune checkpoints, cytotoxic T lymphocyte and immune exhaustion-related markers, as well as cancer signaling pathway biomarkers and cytokines.Conclusion: The CRG risk signature may serve as a robust biomarker for predicting the prognosis and the potential viability of immunotherapy responses. Moreover, the key candidate CRGs might be promising targets to explore the underlying biological background and novel therapeutic interventions in gliomas.","PeriodicalId":13183,"journal":{"name":"Human Genomics","volume":"18 1","pages":"74"},"PeriodicalIF":3.8000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11220998/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Genomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40246-024-00636-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Evidence has revealed a connection between cuproptosis and the inhibition of tumor angiogenesis. While the efficacy of a model based on cuproptosis-related genes (CRGs) in predicting the prognosis of peripheral organ tumors has been demonstrated, the impact of CRGs on the prognosis and the immunological landscape of gliomas remains unexplored.

Methods: We screened CRGs to construct a novel scoring tool and developed a prognostic model for gliomas within the various cohorts. Afterward, a comprehensive exploration of the relationship between the CRG risk signature and the immunological landscape of gliomas was undertaken from multiple perspectives.

Results: Five genes (NLRP3, ATP7B, SLC31A1, FDX1, and GCSH) were identified to build a CRG scoring system. The nomogram, based on CRG risk and other signatures, demonstrated a superior predictive performance (AUC of 0.89, 0.92, and 0.93 at 1, 2, and 3 years, respectively) in the training cohort. Furthermore, the CRG score was closely associated with various aspects of the immune landscape in gliomas, including immune cell infiltration, tumor mutations, tumor immune dysfunction and exclusion, immune checkpoints, cytotoxic T lymphocyte and immune exhaustion-related markers, as well as cancer signaling pathway biomarkers and cytokines.

Conclusion: The CRG risk signature may serve as a robust biomarker for predicting the prognosis and the potential viability of immunotherapy responses. Moreover, the key candidate CRGs might be promising targets to explore the underlying biological background and novel therapeutic interventions in gliomas.

查看原文本刊更多论文

杯突相关特征可预测原发性弥漫性胶质瘤的预后和免疫微环境：一项综合分析。

背景：有证据显示杯突与抑制肿瘤血管生成之间存在联系。虽然基于杯突相关基因（CRGs）的模型在预测外周器官肿瘤预后方面的有效性已得到证实，但CRGs对神经胶质瘤预后和免疫格局的影响仍有待探索：方法：我们筛选了CRGs，构建了一个新的评分工具，并在不同队列中开发了胶质瘤预后模型。随后，我们从多个角度全面探讨了CRG风险特征与胶质瘤免疫格局之间的关系：结果：确定了五个基因（NLRP3、ATP7B、SLC31A1、FDX1 和 GCSH），从而建立了 CRG 评分系统。在训练队列中，基于 CRG 风险和其他特征的提名图显示出卓越的预测性能（1 年、2 年和 3 年的 AUC 分别为 0.89、0.92 和 0.93）。此外，CRG评分与胶质瘤中免疫状况的各个方面密切相关，包括免疫细胞浸润、肿瘤突变、肿瘤免疫功能障碍和排斥、免疫检查点、细胞毒性T淋巴细胞和免疫耗竭相关标记物以及癌症信号通路生物标记物和细胞因子：CRG风险特征可作为预测预后和免疫治疗反应潜在可行性的可靠生物标志物。此外，关键候选CRG可能是探索胶质瘤潜在生物学背景和新型治疗干预的有希望的靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Genomics GENETICS & HEREDITY-

CiteScore

6.00

自引率

2.20%

发文量

审稿时长

11 weeks

期刊介绍： Human Genomics is a peer-reviewed, open access, online journal that focuses on the application of genomic analysis in all aspects of human health and disease, as well as genomic analysis of drug efficacy and safety, and comparative genomics. Topics covered by the journal include, but are not limited to: pharmacogenomics, genome-wide association studies, genome-wide sequencing, exome sequencing, next-generation deep-sequencing, functional genomics, epigenomics, translational genomics, expression profiling, proteomics, bioinformatics, animal models, statistical genetics, genetic epidemiology, human population genetics and comparative genomics.